A Therapeutic Approach to Reducing Contrast-Induced Nephropathy*
RenalGuard® is designed to reduce the toxic effects that contrast media can have on the kidneys. The therapy delivered by the system is based on the theory that creating and maintaining a high urine output can reduce the incidence of Contrast-Induced Nephropathy (CIN).1 In two studies, RenalGuard Therapy® has been shown to reduce the incidence of acute renal failure, and may help reduce morbidity and mortality, as well as hospital costs for the high-risk patient.
RenalGuard RenalGuard Therapy enables the high urine rates that have been shown to reduce the incidence of CIN in at-risk patients.1,2,3 Reducing the transit time of contrast through the kidneys should reduce the ability of that contrast to inflict damage on the kidney. RenalGuard is intended to achieve high urine output safely by automatically and continuously measuring the patient’s urine output and matching that volume by infusing an equal volume of hydration fluid. RenalGuard allows patients to receive as much fluid as they produce while minimizing the risk of over- or under-hydration.
• Clinically demonstrated to reduce CIN in at-risk patients2,3 • Nurse-operated during catheterization, freeing physician to focus on the intervention • Fits within current catheterization time • Found to reduce rates of in-hospital adverse events, including dialysis2,3